Cargando…
Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
Background: Plasma concentration of natalizumab falls above the therapeutic threshold in many patients who, therefore, receive more natalizumab than necessary and have higher risk of progressive multifocal leukoencephalopathy. Objective: To assess in a single study the individual and treatment chara...
Autores principales: | Serra López-Matencio, Jose M., Pérez García, Yaiza, Meca-Lallana, Virginia, Juárez-Sánchez, Raquel, Ursa, Angeles, Vega-Piris, Lorena, Pascual-Salcedo, Dora, de Vries, Annick, Rispens, Theo, Muñoz-Calleja, Cecilia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529019/ https://www.ncbi.nlm.nih.gov/pubmed/34690914 http://dx.doi.org/10.3389/fneur.2021.716548 |
Ejemplares similares
-
Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019) -
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017) -
Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017) -
Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020) -
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
por: Aguirre, Clara, et al.
Publicado: (2020)